BR vs SYRE · P/E 16, rev $7.48B vs $7.60B cap
Broadridge Financial Solutions Inc (BR) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
Broadridge Financial Solutions Inc (BR) is a information technology services company listed on US.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported BR revenue for 2026-06-30 was $7.48B. Net income was $1.12B. Revenue was up 8.5% from 2025-06-30 to 2026-06-30. BR currently screens at market cap $17.65B and trailing P/E 16.3.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
BR currently screens at market cap $17.65B and trailing P/E 16.3. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the BR and SYRE stock pages for the full models.
Not investment advice.